Explore

IT STARTS WITH

FINDING A REGIMEN THAT YOUR PATIENT PREFERS

Every-2-month VOCABRIA + REKAMBYS was preferred by 9 out of 10 trial patients vs daily oral therapy with BIC/FTC/TAF[1]

preferred every-2-month VOCABRIA + REKAMBYS to BIC/FTC/TAF (secondary endpoint; n=382/425)*[1]

At Month 12, participants in the every-2-month VOCABRIA + REKAMBYS arm of the SOLAR study (mITT-E population) responded to a questionnaire assessing their preference for HIV treatment.[1]

*Out of the 447 participants in the every-2-month VOCABRIA + REKAMBYS arm, 425 responded; 90% preferred every-2-month VOCABRIA + REKAMBYS; 5% preferred daily oral therapy with BIC/FTC/TAF; and 5% reported no preference.[1]

TOP FIVE REASONS SELECTED BY THOSE WHO PREFERRED EVERY-2-MONTH VOCABRIA + REKAMBYS IN THE SOLAR STUDY (n=382):[1]
0%

I do not have to worry as much about remembering to take my HIV medication every day

0%

It is more convenient for me to receive injections every 2 months

0%

I do not have to carry my HIV medication with me

0%

I do not have to think about my HIV status every day

0%

I do not have to worry about others seeing or finding my HIV pills

How would you start the conversation with one of your patients?

  • QUESTIONS THAT COULD UNCOVER CHALLENGES WITH DAILY ORAL HIV THERAPY:

Explore the Patient Selection Guide

Contact us for support

BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; HIV=human immunodeficiency virus; mITT-E=modified intention-to-treat exposed; PLHIV=people living with HIV.

References:

  1. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety and tolerability of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV, 12 month results (SOLAR): A randomised open-label, phase 3b non-inferiority trial. The Lancet HIV. 2023. Published Online 8th August 2023. https://doi.org/10.1016/S2352-3018(23)00136-4

REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-230016 | December 2023

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.